Are Abbott and Abbvie the Same Company

AbbVie shares are trading at just 9.4 times expected earnings, one of the lowest valuations among major healthcare stocks. However, the valuation is not as attractive when looking over a longer period of time, as Humira faces the prospect of a drop in sales as a result of competition from biosimilars in the US market. Given the company`s excellent dividend and modest growth prospects that are expected to be strengthened with the Acquisition of Allergan, many investors will likely feel the price is right for AbbVie. As of December 2015, the company employed more than 28,000 people worldwide and supplied products to individuals in more than 170 countries. [5] At the time of the spin-off in 2012, AbbVie was founded as the leading Pharmaceutical Research and Development company under the Abbott brand and acquired Abbott`s core products, including Humira, AndroGel, Vicodin, Kaletra, TriCor and Niaspan. Abbott retained the diagnostics, medical devices and nutrition divisions, as well as the company name and a major generics company. In its first year of trading as a separate publicly traded product, AbbVie (ABBV) generated nearly $18.8 billion in global sales. Abbott acquired BASF`s pharmaceutical business, including Knoll Pharmaceuticals` global operations, expanding the company`s global reach and biotechnology capabilities. Vysis, Inc., a leading genomic disease management company, was acquired the same year to strengthen Abbott`s position in the molecular diagnostics market. Vysis UroVysion`s molecular test for monitoring recurrent bladder cancer has been approved. In January 2014, the company acquired ImmuVen for an undisclosed amount.

[Citation needed] On September 3, 2014, AbbVie and Infinity Pharmaceuticals announced that they had entered into a global collaboration to develop and commercialize duvelisib, Infinity`s PI3K inhibitor for the treatment of cancer patients. On the same day, AbbVie and Calico announced that they have entered into an R&D collaboration to discover, develop and bring to market new therapies for patients with age-related diseases such as neurodegeneration and cancer. California Life Company, operating as Calico, is a subsidiary of Alphabet Inc., which focuses on aging and age-related diseases, led by former Genentech President and CEO Arthur D. Levinson, and Genentech`s former executive vice president and chief medical officer, Hal V. Barron (who later left the company). [9] In the late 90s, Abbott entered the hematology testing market after the acquisition of Sequoia-Turner Corp. It had also acquired MediSense, Inc., which marks the company`s entry into blood glucose monitoring for people with diabetes, and Perclose, a leading vascular occlusion device company, which marks the company`s entry into vascular care. In addition, a next-generation diagnostic system, ARCHITECT, has been launched. Conceived as a research arm of Chicago-based Abbott, AbbVie became a standalone pharmaceutical company in late 2012. Abbott has retained non-scientific interests – from baby food to sports nutrition to heart stents. At the time of the spin-off, Abbott`s management claimed that this decision gave investors the opportunity to objectively evaluate two companies operating in different directions.

Cynical investors, however, suspected that Abbott`s board of directors had set up AbbVie as a repository for some of its patents expiring imminently. AbbVie is a publicly traded U.S. biopharmaceutical company founded in 2013. It was created as a spin-off of Abbott Laboratories. «We wish our colleagues at AbbVie continued success as they become part of a new independent company that is already making a significant difference and focusing on highly specialized, market-leading therapies for some of the world`s most difficult-to-treat diseases,» said Miles D. White, Abbott`s President and Chief Executive Officer. AbbVie`s entire product line consists primarily of 16 drugs, including Lupron (for prostate cancer), Androgel (a testosterone booster) and Creon (pancreatic therapy). But the company`s undisputed heavyweight champion is Humira, an anti-inflammatory drug that happens to be one of the world`s best-selling drugs. On June 25, 2019, AbbVie announced that it would acquire Ireland`s Allergan plc for approximately $63 billion; However, the transaction would not be structured as a tax reversal, and after the transaction, AbbVie (and the group) would retain their U.S. headquarters. for tax purposes; [18] [19] AbbVie`s acquisition of Allergan plc violated antitrust law passed by the Federal Trade Commission on September 4, 2020, resulting in the group divesting certain assets to enable the merger. [20] [21] In July, the company announced the acquisition of Mavupharma, strengthening its cancer drug portfolio.

[22] [23] The company continues to record solid growth, with sales up 5.5% in the third quarter and profits up 12% year over year. Abbott`s largest segment is also the fastest-growing company, with its Cardiovascular and Neuromodulation Products business growing organically by 10.6% in the last quarter. Disclosure: I/we have no position in said shares and do not plan to open positions in the next 72 hours. I wrote this article myself, and it expresses my own opinion. I don`t receive any compensation for this (except from Seeking Alpha). I have no business relationship with a company whose shares are mentioned in this article. We are a company that faces the most difficult health challenges. But we don`t just treat diseases – we want to have a remarkable impact on people`s lives. We are AbbVie, a highly focused, research-driven biopharmaceutical company. Today, AbbVie employs approximately 21,000 people. The COMPANY`s CEO and Chairman of the Board of Directors is Richard A. Gonzalez.

Prior to AbbVie`s separation from Abbott, Gonzalez was an Abbott veteran for 30 years. He served as Executive Vice President of the Pharmaceuticals Group, where he led the global pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as President and Chief Operating Officer before retiring briefly. Our name represents our connection to the past and the future. When we became our own company, AbbVie launched a new type of business – a biopharmaceutical company. We combine the stability, global scale, resources and business capabilities of a pharmaceutical company with the direction and culture of a biotech company. Ausria, a radioimmunoassay assay for the detection of serum hepatitis, was launched in 1972 and marked the beginning of Abbott`s immunodiagnostic activity. A year later, the Abbott Diagnostics division was created to consolidate the company`s diagnostic products and services.

In 2012, the company was accused of illegally marketing Depakote, a best-selling anti-epileptic drug, and agreed to pay $1.6 billion to settle the claims. In 2013, Abbott was fined $524 million for paying bribes to doctors who used Abbott drugs to treat circulatory disorders. A number of blood glucose meters were also recalled in February 2014. Abbott announced in October 2011 that it was splitting into two independent companies as its business became two different investment identities.